Cargando…
Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
Background: Cancer patients with atrial fibrillation (AF) were excluded in the major clinical trials. We therefore investigated the efficacy and safety of novel oral anticoagulant (NOAC) versus warfarin in these patients. Methods: Data were retrieved from Taiwan National Health Insurance Research Da...
Autores principales: | Wu, Victor Chien-Chia, Wang, Chun-Li, Huang, Yu-Tung, Lan, Wen-Ching, Wu, Michael, Kuo, Chang-Fu, Chen, Shao-Wei, Chu, Pao-Hsien, Wen, Ming-Shien, Kuo, Chi-Ching, Chang, Shang-Hung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930400/ https://www.ncbi.nlm.nih.gov/pubmed/31892976 http://dx.doi.org/10.7150/jca.36468 |
Ejemplares similares
-
Safety and Effectiveness of Direct Oral Anticoagulants vs. Warfarin in Patients With Atrial Fibrillation and Endoscopy-Diagnosed Peptic Ulcer
por: Wang, Chun-Li, et al.
Publicado: (2021) -
Novel oral anticoagulant vs. warfarin in elderly atrial fibrillation patients with normal, mid‐range, and reduced left ventricular ejection fraction
por: Wu, Victor Chien‐Chia, et al.
Publicado: (2020) -
Safety and Effectiveness of Non–Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study
por: Wang, Chun‐Li, et al.
Publicado: (2019) -
Efficacy and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study
por: Wang, Chun‐Li, et al.
Publicado: (2018) -
Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
por: Lee, Hsin‐Fu, et al.
Publicado: (2019)